This article somewhat sums it up where investors are looking for the big bang on their buck in healthcare and it’s not here in the US necessarily. Even insurance companies from the US are putting their bets in place, the link below shows a good example of a United subsidiary buying a company that works to get more Chinese drugs and devices to the US and other global locations. The company is about 2-3 subsidiaries down the line here but ultimately under United.
UnitedHealth subsidiary (Ingenix Subsidiary I3) Acquires ChinaGate – Working to Sell Chinese Products Globally
Charles Rivers clients include several big pharma companies and they also perform a lot of animal testing and research. I am guessing we will perhaps see some “pooling” of research information as this moves along too. WuXi is a pharmaceutical outsourcing service provider. 1.6 billion is the price tag. As well as pharma and biomedical products the company also performs GMP testing for medical devices to include delivery systems. BD
If you read a bit further China also produces heparin approved by the FDA, think back to Dennis Quaid there for a moment. BD
The budding promise of China's health-care sector is prompting a spate of deals and share offerings that has defied the broader market malaise.
In the last 10 months, 23 pharmaceutical and heath-care related companies have gone public in mainland China and Hong Kong, according to Dealogic. Many deals are small: 17 of them raised less than $200 million, and eight were for $100 million or less. But cumulatively they have packed a punch, raising $5.37 billion, the data show, with companies continuing to list even through the market turbulence stirred up by debt problems in Europe.
Interest in takeovers has picked up, too. In April, U.S. pharmaceutical-research company Charles River Laboratories International Inc. agreed to buy one of China's largest drug-research contractors, WuXi AppTec Co., for about $1.6 billion in cash and stock. (Activist hedge fund Jane Partners LLC, which owns about 7% of Charles River, is trying to block approval for the deal.)
A turning point for the sector came last September when Sinopharm Group Co., China's largest distributer of pharmaceutical products, successfully raised US$1.3 billion in a Hong Kong IPO.
Helping generate enthusiasm for the stock was its selling point as the only Chinese heparin producer with approval from the U.S. Food and Drug Administration to provide heparin's active pharmaceutical ingredient to the U.S. market